Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Significant Decline in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 467,200 shares, a decrease of 70.2% from the August 31st total of 1,570,000 shares. Based on an average trading volume of 20,860,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.3% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on TNXP shares. Alliance Global Partners increased their price objective on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Wednesday, September 18th. They set a “sell” rating for the company.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC raised its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 335,373 shares of the company’s stock after buying an additional 242,358 shares during the period. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Price Performance

Shares of TNXP traded up $0.00 during trading hours on Wednesday, hitting $0.13. 1,219,386 shares of the stock were exchanged, compared to its average volume of 7,506,082. Tonix Pharmaceuticals has a fifty-two week low of $0.13 and a fifty-two week high of $26.56. The business has a 50-day moving average of $0.36 and a 200-day moving average of $3.30. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The company had revenue of $2.21 million for the quarter, compared to the consensus estimate of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. Equities analysts anticipate that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.